Vincent J. Falanga, MD, FACP

Emeritus Professor, Dermatology

Vincent Falanga


Dr. Vincent Falanga is Emeritus Professor of Dermatology at Chobanian and Avedisian School of Medicine. A dedicated researcher, clinician, and educator, Dr. Vincent Falanga has had a longstanding relationship with the Boston University community. For the past 26 years, Dr. Falanga has been a Professor Biochemistry at the Chobanian and Avedisian School of Medicine (BUSM). In addition, he served as the Assistant Dean of Clinical and Faculty Affairs, as well as the Director of the Boston University Medical Students Ambulatory Medical Clerkship at Roger Williams Medical Center (RWMC), a research and clinical affiliate of the BUSM. From 1998 to 2013, he was the Chairman and Program Director of the Department of Dermatology at RWMC, a major affiliate of Boston University. At that Institution he was also president of the multispecialty practice group. Prior to that, Dr. Falanga held several academic appointments, including an initial one at the University of Pittsburgh School Of Medicine, and then as Professor of Dermatology and Medicine at the Miller School of Medicine at the University of Miami. A graduate of Harvard Medical School, Dr. Falanga received training in Internal Medicine and Dermatology at the University of Miami and the University of Pennsylvania, respectively. He is Board certified in both Medicine and Dermatology. In 2004, he was the President of the Wound Healing Society, the premier research organization in the world dedicated to wound healing.

Vincent Falanga’s remarkable research career began in the fields of molecular and cell biology, evolving over the years to groundbreaking human-based translational research. He made seminal contributions to the expansion and growth of single cells in low oxygen tension and to the effects and transcriptional regulation of transforming growth factor-ß 1 (TGF-ß1). Dr. Falanga later focused his efforts on human recombinant growth factors and was the first to use a recombinant growth factor (EGF) in human non-healing wounds. He showed that systemic anabolic steroids can heal the painful skin ulcers due to cryo-fibrinogenemia and that doubling the dose of systemically administered pentoxifylline will heal venous ulcers. In 1998, he was the lead author in the use of living bioengineered skin in non-healing wounds, which led to the first ever FDA approval of bioengineered skin for accelerating wound closure. In 2007, he was the first to successfully use autologous cultured bone marrow-derived mesenchymal stem cells in human chronic wounds. In 2013 Dr. Falanga moved his clinical research and basic science laboratory at the main campus of the medical school, becoming the first recipient of the “Barbara A. Gilchrest Professorship”. At the same time, he became the Vice-Chair for research in the Department of Dermatology and the residency program director. In those roles Dr. Falanga spearheaded and coordinated many of the research projects related to tissue injury, repair processes, and regeneration. He also recruited junior research faculty members to the Department of Dermatology. Between 2013 and 2016 Dr. Falanga established a newly constructed Good Manufacturing Practice (GMP) facility in which he oversaw the research and development of novel treatments utilizing the therapeutic potential of stem cells in the care of chronic wounds caused by disorders ranging from diabetes to autoimmune disease. The GMP facility remains a potential research laboratory to enrich the translational capabilities of the Medical Center in Dermatology and other specialties. Up to 2016 his project with stem cells in human wounds was funded by the National Institutes of Health. Overall and throughout his scientific career, Dr. Falanga has received more than $45 million in research funding, mostly from the National Institutes of Health (NIH).

Other Positions

  • Research Professor, Biochemistry & Cell Biology, Boston University Chobanian & Avedisian School of Medicine


  • Harvard Medical School, MD
  • College of the Holy Cross, BA


  • Published on 9/19/2023

    Nahm WJ, de Imus G, Mathe CA, Saap L, Joseph S, Chen S, Falanga V. A case of markedly impaired wound repair with angiostatic pazopanib in a patient who had Mohs surgery for a basal cell carcinoma. SAGE Open Med Case Rep. 2023; 11:2050313X231200967. PMID: 37736143.

    Read at: PubMed
  • Published on 8/25/2023

    Kida M, Fatima I, Rozhkova E, Otero-Viñas M, Wu M, Kalin JH, Cole PA, Falanga V, Alani RM, Sharov AA. Inhibition of the CoREST Repressor Complex Promotes Wound Re-Epithelialization through the Regulation of Keratinocyte Migration. J Invest Dermatol. 2024 Feb; 144(2):378-386.e2. PMID: 37633457.

    Read at: PubMed
  • Published on 12/2/2022

    Falanga V. The dilemma of hard-to-heal wounds: stimulation versus energy consideration. J Wound Care. 2022 Dec 02; 31(12):1015. PMID: 36475856.

    Read at: PubMed
  • Published on 7/21/2022

    Falanga V, Isseroff RR, Soulika AM, Romanelli M, Margolis D, Kapp S, Granick M, Harding K. Chronic wounds. Nat Rev Dis Primers. 2022 Jul 21; 8(1):50. PMID: 35864102.

    Read at: PubMed
  • Published on 5/19/2022

    Falanga V, Grada A, Otero-Vinas M, Lin X, Yufit T, Fiore D, Carson P. Autologous Cultured Bone Marrow-Derived Mesenchymal Stem Cells in a Fibrin Spray to Treat Venous Ulcers: A Randomized Controlled Double-Blind Pilot Study. Surg Technol Int. 2022 May 19; 40:47-54. PMID: 35168289.

    Read at: PubMed
  • Published on 6/28/2021

    Otero M, Lin X, MacLauchlan S, Carson P, Falanga V. Dermal Fibroblasts from Chronic Wounds Exhibit Paradoxically Enhanced Proliferative and Migratory Activities that May be Related to the Non-Canonical Wnt Signaling Pathway. Surg Technol Int. 2021 06 28; 39:59-66. PMID: 34181242.

    Read at: PubMed
  • Published on 11/10/2019

    Obagi Z, Damiani G, Grada A, Falanga V. Principles of Wound Dressings: A Review. Surg Technol Int. 2019 11 10; 35:50-57. PMID: 31480092.

    Read at: PubMed
  • Published on 10/1/2018

    Grada A, Mervis J, Falanga V. Research Techniques Made Simple: Animal Models of Wound Healing. J Invest Dermatol. 2018 10; 138(10):2095-2105.e1. PMID: 30244718.

    Read at: PubMed
  • Published on 10/2/2017

    Ferrer-Sola M, Sureda-Vidal H, Altimiras-Roset J, Fontsere-Candell E, Gonzalez-Martinez V, Espaulella-Panicot J, Falanga V, Otero-Viñas M. Hydrosurgery as a safe and efficient debridement method in a clinical wound unit. J Wound Care. 2017 10 02; 26(10):593-599. PMID: 28976826.

    Read at: PubMed
  • Published on 2/1/2017

    Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. J Invest Dermatol. 2017 Feb; 137(2):e11-e16. PMID: 28110712.

    Read at: PubMed

View 318 more publications: View full profile at BUMC

View all profiles